Clinical Trial Update: Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the optimal dose of Org 36286 to induce monofollicular ovulation in WHO Group II anovulatory infertility; status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility

Drugs mentioned

• Org 36286

Snippet

Sponsor: Organon and Co | Conditions: Infertility | Phase 2 | Status: COMPLETED